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ABSTRACT
Otherwise unexplained clinical signs of infection in patients with long-term tunnelled or totally
implanted central venous access devices (CVADs) are suspected to be CVAD-associated. Diagnostic
methods include catheter swabs, blood cultures and cultures of the catheter tip or port reservoir. In the
case of a suspected CVAD-related bloodstream infection in paediatric oncology patients, in-situ
treatment without prompt removal of the device can be attempted. Removal of the CVAD should be
considered if bacteraemia persists or relapses ‡ 72 h after the initiation of (in-vitro effective) antibacterial
therapy administered through the line. Timely removal of the device is also recommended if the patient
suffers from a complicated infection, or if Staphylococcus aureus, Pseudomonas aeruginosa, multiresistant
Acinetobacter baumannii or Candida spp. are isolated from blood cultures. Duration of therapy depends on
the immunological recovery of the patient, the pathogen isolated and the presence of related
complications, such as thrombosis, pneumonia, endocarditis and osteomyelitis. Antibiotic lock
techniques in addition to systemic treatment are beneﬁcial for Gram-positive infections. Although
prospectively controlled studies are lacking, the concomitant use of urokinase locks and taurolidine
secondary prophylaxis seem to favour catheter salvage.
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INTRODUCTION
Long-term central venous access devices
(CVADs) have been used for at least 20 years in
the treatment of paediatric oncology patients.
Such devices are either tunnelled CVAD devices
(single-lumen or multi-lumen) with a sub-cuta-
neous cuff adjacent to the catheter exit site, such
as the Broviac (or Hickman or Groshong) model
[1,2], or totally implanted port systems with
sub-cutaneous reservoirs [3,4]. Routine use of
long-term CVADs offers considerable advantages
for both patients and the treatment team. These
catheters are used as a means of straightforward
and safe central venous access to administer
cytotoxic agents, antimicrobial agents, analgesics
and blood products. They facilitate hyper-osmolar
parenteral nutrition in patients with high-grade
mucositis who are unable to tolerate enteral
feeding [5], and allow painless blood collection.
In emergency situations, e.g., septic shock,
CVADs provide immediately available large-
lumen access for high-volume treatment or for
catecholamine administration.
Implantation of foreign material into the vas-
cular system enhances the risk for catheter-related
infections [3,6–11]. In addition, the use of CVADs
may be accompanied by mechanical problems
(dislocation, catheter rupture, paravasation, chy-
lothorax) [12–14], and also poses an increased risk
for thrombotic complications for the patient [15–
18]. In two recent prospective studies involving
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paediatric oncology patients, infectious complica-
tions were dominated by the mechanical aspects,
with infections accounting for 1.3 (of 4.5) and 0.87
(of 1.7) events ⁄ 1000 CVAD utilisation days (UDs),
respectively [15,19].
If both inpatient and outpatient catheter days are
counted as reference parameters (UDs), the repor-
ted estimates of infectious complications may be
substantially biased, as most events involving
catheter use and manipulation take place during
an inpatient treatment period. According to a
prospective study of CVAD-related infections that
made a distinction between these two options, the
incidence rate during hospital stay was 25-fold
higher (7.4 vs. 0.3 ⁄ 1000 UDs) [4]. In the interim
evaluation (as at 17 June 2005) of the prospective
multicentre surveillance study for nosocomial
infections in paediatric oncology (http://www.
onkopaednki.de), the cumulative incidence densi-
ties for CVAD-related bloodstream infections are
2.21 ⁄ 1000 UDs (25 382 cumulative inpatient UDs)
for Broviacs, and 3.73 ⁄ 1000 UDs (13 675 cumula-
tive inpatient UDs) for ports. The risk of infectious
complications is obviously highest during inten-
sive use of the CVAD in the hospital.
Based on the description of a few practice-
related issues concerning the aetiology and patho-
genesis of CVAD-related infections, this review
discusses the basic principles involved in the
management of CVAD-associated infection in
paediatric oncology patients. The conclusions
may help to support paediatric oncologists in
their individual decision-making processes [20–
23]. This review refers exclusively to long-term,
implanted CVADs. Non-tunnelled, central venous
catheters are used in paediatric oncology only
rarely for a treatment period of 2–3 weeks.
IMPORTANT PATHOGENS
In CVAD-related infections, most bacterial path-
ogens isolated from swabs, central-line blood
cultures or explanted catheter materials are
Gram-positive bacteria, particularly methicillin-
resistant, coagulase-negative staphylococci
(CoNS or methicillin-resistant Staphylococcus epi-
dermidis; MRSE) originating from the proximal
connecting end of the catheter (hub) [24,25] or
from the skin at the exit site of the Broviac or the
port needle [26,27]. There is some evidence that
colonised gastrointestinal mucosal surfaces are a
relevant source of infection with CoNS in
patients receiving long-term parenteral nutrition
[28,29].
CVAD-related infections with Staphylococcus
aureus (including methicillin-resistant S. aureus;
MRSA) are of utmost clinical relevance because of
their high morbidity and an increased risk of local
or systemic suppurative complications [30].
Microorganisms derived from the intestine (e.g.,
enterococci, including vancomycin-resistant en-
terococci; VRE) [31] or the oropharynx [32] (e.g.,
a-haemolytic streptococci: viridans streptococci
and Stomatococcus mucilaginosus or Leuconostoc
spp.) are less common [27,33,34] aetiological
agents in catheter infections. CVAD infections
caused by Gram-negative bacteria, such as Pseu-
domonas aeruginosa, Burkholderia cepacia, Klebsiella
spp., Stenotrophomonas maltophilia [35] or Acinetob-
acter baumannii [36], are often accompanied by
septic shock [37]. Candida spp., among which
Candida parapsilosis seems to be particularly
important in CVAD-related infections [38–44],
may also cause life-threatening CVAD-related
infections, such as endocarditis or septic thrombo-
phlebitis.
Aspergillus spp. [45]. or atypical mycobacteria
[46] cause rare necrotising skin infections at the
exit site of a CVAD. In these cases, immediate
removal of the device is required.
PATHOGENIC FACTORS RELEVANT
FOR TREATMENT
Microbiological colonisation of a CVAD usually
occurs within 24 h of catheter implantation.
Initially, colonisation may involve the catheter
lumen, originating from contamination of the
catheter hub [25] or the extra-luminal surface
following contamination of the Broviac exit site
(port puncture site) [47]. Primary contaminated
intravenous infusions [48] or haematogenous
CVAD colonisation secondary to bacteraemia
from a distant focus are less common events
[32,49]. Bacteria capable of binding to foreign
materials, cross-linked with extracellular glyco-
polysaccharides, ﬁbrin and ﬁbronectin, constitute
the main problem [26]. The rapid formation of
such an extracellular bioﬁlm matrix prevents an
adequate immune response against the adhering
bacteria [50–53]. The bioﬁlm also impedes the
eradication of microorganisms, despite treatment
with antimicrobial agents that are highly effective
in vitro [54–57].
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The efﬁcacy of an antimicrobial agent used for
the treatment of CVAD-related infections is based
on its ability to kill bacteria that either adhere to
plastic materials or are embedded in a bioﬁlm
[54,55,58,59]. Sufﬁcient concentrations of the anti-
biotic must be available for a deﬁned period of
time at the infection site. In the case of bioﬁlm-
embedded bacteria, this means that the con-
centration has to be ‡ 100-fold or, better still,
1000-fold above the MIC for the pathogen for
several hours [60,61]. In addition, attempts should
be made to disrupt the integrity of the bioﬁlm
with urokinase [58,62,63] or ethanol [64] before
administration of the antibiotic.
DEFINITIONS AND DIAGNOSTIC
METHODS
Local inﬂammatory signs (pain, redness, swelling
and secretion) at the catheter exit site, or adjacent
to the sub-cutaneous tunnel, guide the clinical
diagnosis to a local CVAD-related infection.
However, local symptoms may not be evident
clinically in patients with severe neutropenia
(< 0.5 · 109 neutrophils ⁄L). Swabs from the entry
site of the catheter, before local treatment with an
antiseptic, are used to identify a pathogen in local
infections. When the outlet point is crusted over,
the crust should be removed carefully with sterile
gauze pads moistened with sterile saline 0.9%
w ⁄ v, after which a swab for aerobic culture
should be taken from the wound area. Routine
blood culture of samples collected from the
catheter, or swabs from an exit site without any
clinical sign of inﬂammation, is a waste of
resources for patients presenting without symp-
toms, with the exception of patients undergoing
stem-cell transplantation [65–67].
Fever is often the only sign of CVAD-associated
bacteraemia. The onset of fever in a patient
immediately after ﬂushing the CVAD lumen, or
after connecting it to an infusion, should trigger
the suspicion of catheter colonisation or infection.
It is important to realise that the CVAD poses a
higher risk of severe bloodstream infection for the
patient, even without neutropenia [68–70]. Thus,
central blood cultures should be performed for
every febrile oncology patient with a CVAD,
irrespective of the actual leukocyte count.
The term ‘CVAD-associated infection’ refers to
an event indicative of a systemic infection, char-
acterised by clinical signs such as fever, chills,
lowering of arterial blood pressure, reduced
blood ﬂow through the circulatory periphery
(capillary ﬁlling time > 3 s) [71] and oliguria, with
or without positive blood cultures, in a patient
with a CVAD and no other detectable focus [72].
The additional clinical symptoms distinguish a
CVAD-associated infection from ‘fever of un-
known origin’. The term ‘CVAD-associated infec-
tion’ following this deﬁnition is adequate for
epidemiological surveillance studies [4], but does
not guarantee that the CVAD is the source of the
infection or the source of a positive blood culture.
Attempts have been made to conﬁrm an infec-
tion as ‘CVAD-related’ using the criteria listed in
Table 1. According to these deﬁnitions, either
catheter removal or the performance of quantita-
tive blood cultures before antibiotic treatment is
required. However, a CVAD cannot be replaced
without considerable burden to the patients and
their families and signiﬁcant ﬁnancial expendi-
ture (full anaesthesia and perhaps the temporary
insertion of a short-term central venous catheter).
On the other hand, antibacterial treatment of a
device suspected to be the source of infection is a
feasible and successful task in many patients, and
initial attempts are thus almost always based on
in-situ treatment via the indwelling catheter
[21,73–76]. Semiquantitative cultures from the
catheter tip to conﬁrm CVAD infection are not
available from such patients [24,77–80]. Even after
Table 1. Various forms of central venous access device (CVAD)-related infection [3,20–23,73,77,78]
Conﬁrmed infection: CVAD-related infection Probable infection Potential infectiona
Same pathogen detected at the tip of the catheter
(in the port chamber or pocket) and in the BC
Local infection at the exit site and positive BC ‘Typical’ pathogen of CVAD-related infections
detected in the BCb
DTP (between central and peripheral venous blood culture) > 2 h Positive BC and response of refractory fever
within 48 h of catheter removal
Positive BC and and absence of any other focus
in patient with CVAD
Quantitative blood culture: CFU from catheter ‡ 10-fold higher than
CFU from from simultaneous, peripheral venous BC
Colonisation of the catheter tip in the quantitative
culture in excess of the limit stipulated for the
method (generally > 15 CFU)
aThis corresponds to ‘CVAD-associated infection’.
bIn the case of skin microorganisms, such as coagulase-negative staphylococci, two consecutive positive cultures (at least in two blood culture bottles) are required.
BC, blood culture; DTP, differential time-to-positivity.
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CVAD explantation, these cultures do not yield
reliable results, as the catheter has almost always
been exposed to preceding antibacterial chemo-
therapy [40]. In explanted ports, culturing of
deposits from the reservoir may be a more
sensitive method than culturing the catheter tip
[3].
Various methods involving the simultaneous
culture of central venous and peripheral venous
blood samples have been described in attempts
to identify a non-explanted CVAD as the source
of bacteraemia [73,77,78,81–84]. A comparative
blood culture [85] can be a clear-cut indication if,
compared with a peripheral venous blood sample
collected at the same time, the same pathogen can
be detected with a colony count at least ﬁve-fold
higher in the blood removed from the CVAD
[21,86]. An alternative, less expensive, method
involves determination of the differential time-to-
positivity (DTP) for central venous vs. peripheral
venous blood, i.e., the time between collection
and the ﬁrst positive signal in an automated blood
culture system [77,87,88]. If the DTP of the central
blood culture is ‡ 120 min less than that for the
peripheral culture, then catheter infection is sug-
gested [89,90]. In a prospective study, Blot et al.
[88] reported a sensitivity of 94% and a speciﬁcity
of 91% for this method, while in a prospective
study involving paediatric oncology patients (33
episodes), Gaur et al. [91] reported a sensitivity of
88.9% (100% speciﬁcity, with a positive predic-
tive value of 100%, and a negative predictive
value of 89–96%). In paediatric oncology, pros-
pective use of the DTP method may be useful for
evaluating outbreaks of CVAD-associated infec-
tions. In such cases, typing of the presumably
epidemic isolates from blood cultures should also
be performed (e.g., by pulsed-ﬁeld gel electro-
phoresis) [84,92].
SHOULD THESE METHODS BE
APPLIED TO PAEDIATRIC
ONCOLOGY PATIENTS?
As a rule, the approaches described above lead to
signiﬁcant problems among paediatric oncology
patients that, after considering the anticipated
beneﬁts, mitigate against the routine collection of
samples for additional peripheral venous cul-
tures. Collection of samples for peripheral venous
blood cultures in a patient with a CVAD from
which blood can be drawn easily is not part of the
standard treatment protocol in many institutions,
and quantitative cultures do not form part of the
routine diagnostic procedure in most diagnostic
microbiology laboratories. There is a substantial
risk for contamination of the peripheral venous
culture, particularly with non-cooperative chil-
dren. Furthermore, acceptance of the need to
collect additional peripheral blood samples from
a centralised child with fever is low, as this
procedure does not generally affect therapeutic
decision-making [93]. Indeed, a study from
St Jude Children’s Hospital (Boston, MA, USA)
found that peripheral venous blood cultures were
collected from only 58% of patients with febrile
neutropenia and a CVAD, despite a written
hospital-wide policy [86].
METHODS TO CONFIRM THE
DIAGNOSIS WITHOUT PERIPHERAL
PUNCTURE
One method to conﬁrm the diagnosis in blood
drawn from a CVAD is the direct detection of
pathogens using the acridine orange leukocyte-
cytospin test [94]. A meta-analysis has shown that
this procedure has good speciﬁcity and adequate
sensitivity [95], but it is too expensive for routine
clinical use. As an alternative, Franklin et al. [86]
found that the number of CFU ⁄mL was at least
ﬁve-fold different in blood taken from different
lumina for 76 (55.9%) of 136 cases of bacteraemia
in patients with a double-lumen Broviac ⁄Hick-
man device, and that this could identify the
infected lumen with a positive predictive value of
92.2% [86]. The same authors reported sensitivity,
speciﬁcity and positive predictive values of
75.5%, 69.1% and 79.3%, respectively, with a
threshold value of > 100 CFU ⁄mL cultured from
one lumen. Special tools for collecting in-situ
cultures from the small lumen of a paediatric
CVAD with a protected brush may be available in
the near future [96].
Taken together, the minimal requirements for a
paediatric oncology patient with fever and a
CVAD include the collection of samples for at
least two central blood cultures (i.e., aerobic and
anaerobic) in order to rule out skin contamin-
ation, e.g., by CoNS and corynebacteria. In the
case of multiple-lumen CVADs, a sample for
blood culture should be taken from every lumen
before treatment because results differ by up to
30% [93,97]. Culture of a larger volume of blood
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increases the sensitivity to a greater extent than
does the cultivation of several smaller samples
[98–100]. A heparin (not a taurolidine or EDTA)
lock can be added to the culture bottle ⁄ tube
[101,102]. The use of aerobic and anaerobic blood
culture sets can increase the detection rate of
facultative anaerobic microorganisms and should
be a standard procedure for severely immuno-
compromised patients [100,103].
IS IN-SITU TREATMENT WORTH A
TRY?
Most episodes of CVAD-associated bacteraemia,
especially those caused by CoNS (or MRSE), can
be cured without surgical removal of the CVAD.
In two prospective studies focusing on empirical
antibacterial chemotherapy, surgical removal of
the CVAD was necessary in only ten (2%) of 500
episodes of febrile neutropenia in paediatric
oncology patients with a CVAD [104,105]. During
a prospective 10-month surveillance study of
nosocomial infections, two (6.3%) of 32 Broviac
catheters, and four (6.7%) of 60 ports, had to be
removed following unsuccessful in-situ treatment
over the course of the 10-month study period [4].
Although healing rates are lower when a CVAD is
conﬁrmed as the source of bacteraemia (i.e.,
CVAD-related bacteraemia or sepsis), most de-
vices infected with CoNS may still be salvaged
with in-situ treatment [40,76].
TREATMENT PRINCIPLES
Paediatric oncology patients presenting with
signs of a CVAD infection should be referred
promptly to a treatment centre where constant
care by experienced oncologists is guaranteed
[106]. Superﬁcial inﬂammation at the catheter exit
site can be treated in non-granulocytopenic
patients by changing the dressing on a daily basis
and by application of local antiseptics, such as
octenidine hydrochloride [107], polyvidone iod-
ine [108], polyhexanide [109] or Leptospermum
honey, with proven antibacterial efﬁcacy [110].
Topical antibiotic ointments foster the selection of
resistant isolates and should therefore be avoided
completely, or applied only in the short term
(maximum 5 days) if in-vitro testing suggests
bactericidal efﬁcacy. Mupirocin should be used
exclusively for cases of colonisation or infection
with MRSA [111]. In addition, systemic antibac-
terial chemotherapy should be administered to
neutropenic patients with local signs of infection,
or following the onset of marked inﬂammation of
the skin or soft-tissue, regardless of the granulo-
cyte count.
If CVAD is suspected as being the source of a
systemic infection, empirical or targeted antimi-
crobial treatment, with or without removal of the
device, are possible options. In this context, a
distinction should be made at the onset of
symptoms between complicated and uncompli-
cated infections [21,23,40,73,74]. A CVAD infec-
tion is considered to be complicated in the event
of:
• Tunnel infection (Broviac) or pocket infection
(port)
• Sepsis with symptoms of shock or persistent
end-organ dysfunction
• Association with a central venous thrombosis
or endocarditis
• Catheter infection with osteomyelitis or with
metastatic seeding of septic emboli (ecthyma
gangrenosum of the skin and the adjacent soft-
tissue is a typical complication of systemic
infection with Pseudomonas spp.).
In all cases of complicated CVAD-associated
infections, early removal of the CVAD should be
considered after taking into account all available
information and the patient’s individual situation.
As indicated above, further complications must
be ruled out by adequate diagnostic efforts,
including Doppler ultrasonography, echocardiog-
raphy, optional chest X-rays, computed tomogra-
phy, phlebography or magnetic resonance
angiography [112,113].
If the blood culture yields speciﬁc pathogens,
such as S. aureus [21,30,73,114], P. aeruginosa [37],
multiresistant A. baumannii [115] or atypical my-
cobacteria [46], timely removal of the device is
recommended by most experts, as cure rates are
otherwise low and the risk of septic complications
is high. Rubin et al. [76] reported a favourable
outcome in 67% of all patients with S. aureus
infections without removal of the device, but this
should be interpreted with caution as there were
only six cases.
Uncomplicated CVAD infection usually re-
sponds clinically to empirical or targeted treat-
ment within 72 h. Subsequently, at least two
sterile blood cultures should conﬁrm the thera-
peutic success from a microbiological angle.
Following an antibiotic-free interval, the blood
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cultures should be retested. An algorithm for
management of uncomplicated CVAD infection
(Fig. 1) proposes a clinical workﬂow for paediat-
ric oncology units, subject to local institutional
prerequisites. The treatment regimens ﬁxed in a
department-speciﬁc standard should make use of
synergic effects between antibiotics with various
mechanisms of action (e.g., teicoplanin and net-
ilmicin or fosfomycin for Gram-positive patho-
gens, or piperacillin–tazobactam or ceftazidime
Febrile paediatric oncology patient with a long-term CVAD
Blood cultures from all CVAD lumen: aerobic, anaerobic (fungal)
Empirical antimicrobial therapy
BC yields
CoNS (MRSE), 
Corynebacterium spp.,
Enterococcus spp.
BC yields
Staphylococcus aureus,
Gram-negative isolate,
Candida spp.
Use a glycopeptide empirically,
if a Gram-positive BC is reported
Adjust antimicrobial therapy
to the results of in-vitro sensibility testing.
Use targeted antibiotic lock therapy
(daily change, 10 days)
Adjuvant
Urokinase?
Taurolidin?
Timely removal of the device
in case of complicated
CVAD infections
and unsuccessful therapy
Without clinical deterioration:
try in-situ treatment for 72 h
Combination therapy (in-vitro testing)
Consider early removal of the device
Exclude secondary complications
Patient afebrile and stable after 72 h:
Consider further outpatient management
Prophylaxis of recurrence with 
Taurolidine lock?
Treat for at least 10 days IV (Staphylococcus aureus ≥ 21 days)
Fig. 1. Orienting therapeutic algorithm for patients with uncomplicated central venous access device (CVAD)-associated
infection (BC, blood culture; CoNS, coagulase-negative staphylococci; MRSE methicillin-resistant Staphylococcus epider-
midis). If intensive care is required and the patient remains unstable, it might be essential to remove the CVAD
immediately.
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and tobramycin or amikacin for Gram-negative
pathogens). Within the scope of secondary pro-
phylaxis, an attempt can be made to decrease the
enhanced risk for recurrent infection [23] using
antimicrobial lock solutions [116–118].
GLYCOPEPTIDES
Glycopeptides are still the mainstay for the treat-
ment of CVAD-related infections. Therefore, a re-
examination of important features of teicoplanin
and vancomycin used in this context is reasonable.
Glycopeptides are active exclusively against
Gram-positive bacteria, including MRSE and
MRSA [119], enterococci (not VRE), penicillin-
resistant viridans streptococci and penicillin-
resistant Streptococcus pneumoniae, Listeria spp.,
opportunistic corynebacteria (such as Corynebacte-
rium jeikeium [27,120] or Corynebacterium urealyti-
cum [121,122]) and Bacillus cereus [123–125]. The
bactericidal effect of glycopeptides against Gram-
positive bacteria correlates with the level achieved
above the MIC for the isolate [126–128], and
treatment aims to achieve a prolonged period
during which the concentration of the drug
remains at least ten-fold greater than the MIC.
Another way to quantify the pharmacokinetic
attempt is to aim for an AUC ⁄MIC ratio of > 125.
Importantly, the peak level of the glycopeptide is
not important for the bactericidal effect [129].
Graninger et al. [130] suggested that trough levels
(plasma level just before the next dose) should be
measured in patients with severe Gram-positive
infections, such as septic thrombophlebitis or
endocarditis, as a consequence of catheter-related
infection. Trough levels of 20–30 mg ⁄L for
teicoplanin and 10–20 mg ⁄L for vancomycin
indicate (indirectly) a high level of exposure to
the drug and may contribute to a better outcome.
Harding et al. [131] came to the same conclusion
for patients with severe sepsis caused by
S. aureus. Serum creatinine measurements and
audiometric follow-ups should be performed for
patients who receive additional drugs with poten-
tially adverse ototoxic and nephrotoxic effects.
Glycopeptides should not be used for infections
caused by methicillin-sensitive bacteria; this may
result in a delayed clinical response, since peni-
cillin derivatives display faster time-to-kill prop-
erties [132]. Some Staphylococcus haemolyticus
isolates show reduced susceptibility to teicopla-
nin (MIC > 4 mg ⁄L) or are teicoplanin-resistant
(MIC > 16 mg ⁄L) [133–136], but our own paedi-
atric oncology department has not observed a
shift in sensitivity among the Gram-positive
pathogens isolated from CVAD-related infections,
despite use of teicoplanin for > 10 years. Many
paediatric oncology centres in Europe prefer to
use teicoplanin, since it is as effective as and less
toxic than vancomycin [137–141], needs no trough
level determination to prevent nephrotoxic or
ototoxic adverse events [131,136], and does not
cause ‘red-man syndrome’ if it is administered in
< 60 min [142,143]. Another obvious advantage is
the standard practice of administering teicoplanin
once-daily after the ﬁrst two doses (administered
every 12 h). This allows outpatient treatment for
afebrile clinically stable patients. Considering
the pharmacokinetic–pharmacodynamic relation-
ships described above, it seems reasonable to
extend the period of administration to several
hours [144]. As an adjunct, antibiotic lock therapy
can be added to the short infusion. The crude
acquisition costs for teicoplanin are about ﬁve-
fold higher than those for vancomycin, but this is,
at least in part, compensated for by the lack of any
need for drug monitoring and the once-daily
treatment schedule [145].
Glycopeptides should not be used routinely for
empirical therapy in febrile neutropenic patients
without additional signs of sepsis who have been
treated previously with piperacillin–tazobactam
or a carbapenem, provided there is no sign of
local infection of the CVAD device or a positive
blood culture [146,147]. The presence of a CVAD
does not justify the uncritical use of a glycopep-
tide [148]. Nevertheless, patients with acute
myeloid leukaemia after high-dose treatment
with cytosine arabinoside face a substantially
increased risk of sepsis and pneumonia caused
by viridans streptococci, and seem to have an
advantage in terms of lower mortality if a glyco-
peptide is used as early as possible during the
course of the infection [33,149,150]. In patients
treated empirically, the cessation of the glycopep-
tide should be considered regularly after 72 h, if
blood cultures remain negative, to avoid the
selection of VRE [151–154].
DURATION OF TREATMENT
Intravenous antimicrobial treatment of a CVAD-
related infection should be administered through
the CVAD over a period of ‡ 10 days. Prolonged
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treatment of ‡ 21 days is required if S. aureus has
been detected in blood cultures [30,155], for
4–6 weeks with thrombosis and endocarditis (bac-
tericidal combination therapy), and for 6–8 weeks
for patients with secondary osteomyelitis
[130,156]. Before implanting another long-term
CVAD, at least two negative blood cultures are
required to conﬁrm eradication of the pathogen
[73,74]. In the case of CVAD-associated fungal
infections, treatment should be continued for
‡ 14 days after the ﬁrst blood culture and after
clinical symptoms improve [43].
ADJUVANT TREATMENT MEASURES
The adjuvant treatment methods outlined below
(antibiotic lock, ethanol, taurolidine and urokin-
ase) are, in many places, already standard prac-
tices based on pathogenic considerations, case
reports and open-label, controlled studies. To
date, prospective, controlled, double-blind stud-
ies investigating adjuvant use in paediatric cancer
patients with CVAD-related infections are lack-
ing. The use of adjuvant treatment measures can
prove extremely useful, but a written standard
procedure for their use should be included in the
clinical workﬂow.
Antibiotic lock technique
Guidelines published by the Infectious Diseases
Society of America [21] advocate catheter locking
for 14 days (changed daily) in addition to 7-day
systemic administration of antibacterial treatment
for cases of uncomplicated, catheter-related bact-
eraemias caused by CoNS, Staph. aureus and
Gram-negative pathogens.
The antibiotic lock technique (ALT) offers the
advantage of a markedly higher concentration
and longer duration of activity of the antibiotic at
the colonised intra-luminal or infected catheter
surface without the potential side-effects of sys-
temic exposure [40,56,60,63,157–163]. This con-
cept was developed by Messing et al. [164] for the
salvage of indispensable CVADs in patients with
long-term parenteral nutrition. The technique
results in the suppression or eradication of
opportunist bioﬁlm-forming bacteria [63,162,
163,165]. Despite ALT, such patients face an
increased risk for recurrent infections with an
identical isolate [166,167]. In local, systemic or
extra-luminal CVAD-related infections, ALT
should be combined with systemic treatment, at
least for the ﬁrst 72 h. The short-term success
rates in adults presenting with various underly-
ing diseases and treated with ALT, whether alone
or combined with systemic therapy, have been
reported as 30–100% [56,157,158,166,168].
No evidence-based recommendations can be
given at the present time concerning the optimal
concentration and intra-luminal dwell time [21].
In the case of bioﬁlm-embedded CoNS, linezolid
2 mg ⁄L seems to result in faster eradication than
vancomycin 10 mg ⁄L or gentamicin 10 mg ⁄L
[26,57,60]. Combination ALTs, especially with
minocycline plus vancomycin, minocycline plus
rifampicin, vancomycin plus rifampicin, or mino-
cycline plus EDTA [53,169–172], are clearly more
effective in vitro against bioﬁlm-forming CoNS
than the individual compounds. Rifampicin and
minocycline share the advantage of playing vir-
tually no role in the targeted treatment of bacterial
infections in this patient group. Thus, the risk of
selecting a resistant pathogen is low.
The stability of various antibiotic–heparin com-
binations (Table 2) has been documented both
in vitro and in vivo [60,162,173–175]. A combination
of vancomycin 25 mg ⁄L (i.e., 2.5 mg added to
100 mL of NaCl 0.9% w ⁄ v) and heparin
100 000 U ⁄L (i.e., 10 000 U added to 100 mL of
NaCl 0.9% w ⁄v) is stable and, furthermore, bacte-
ricidal for ‡ 14 days. Vancomycin, cefazolin, ceft-
azidime (at ﬁnal concentrations of 500 mg ⁄L) and
ciproﬂoxacin (ﬁnal concentration of 125 mg ⁄L) are
stable for 7 dayswith 100 000 Uheparin ⁄L (Table 2
and overview by Trautmann and Krier [168]).
Ethanol instillation
Dannenberg et al. [64] have reported positive
experiences with ethanol instillations (2.3 mL of
Table 2. Antimicrobial lock solutions [60,162,168,173–175]
Active ingredient Concentration (mg ⁄L)
Vancomycina 0.025–10
Teicoplanina 0.025–2.5
Linezolida 0.2–2
Amikacina,b 1–10
Gentamicin 1–10
Ciproﬂoxacin 0.125–2
Ceftazidime 0.5–2
Amphotericin B desoxycholate 2 (in glucose 5% w ⁄v)
aStable for ‡ 24 h without loss of efﬁcacy when combined with heparin 100 U ⁄mL.
bVancomyin 25 mg ⁄L + amikacin 25 mg ⁄L + heparin 100 000 U ⁄L in NaCl 0.9%
w ⁄v [174].
Note: Standard antibiotic lock technique ampoules prepared by the hospital
pharmacy must be protected carefully against contamination with bacteria and
fungi, and should be ﬁlter-sterilised and stored in a refrigerator.
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ethanol 74% v ⁄ v, dwell time of 20–24 h) and
intra-luminally infected Broviac catheters [64].
The Broviac catheter had to be removed during
the clinical course of the infection in only one
(2.6%) of 39 infectious episodes. The ethanol lock
must not be aspirated, as the catheter then
immediately becomes occluded with denatured
blood. Mild symptoms, such as fatigue, transient
dizziness and headaches, were observed to be
related to the ethanol ﬂush.
Taurolidine
Taurolidine is derived from the biogenic amino-
acid taurine. Taurolidine possesses a broad bac-
tericidal and fungicidal (Candida spp.) efﬁcacy
spectrum in vitro [61,176,177]. Unlike antibiotic
lock solutions, the use of taurolidine does not
depend on the resistance proﬁle of the isolate
(taurolidine is also active against MRSE, MRSA,
VRE and Gram-negative bacteria producing
extended-spectrum b-lactamases). Thus, use of
taurolidine should not select antibiotic-resistant
microorganisms.
In primary prophylaxis, taurolidine appears to
inhibit formation of the intra-luminal bioﬁlm
[54,61,116], but it is not yet known deﬁnitively
whether taurolidine can penetrate an existing
bioﬁlm [50]. Since taurolidine is metabolised to
taurine amide, taurine and CO2, taurolidine is not
toxic following intravenous administration. John-
ston et al. [178] added taurolidine to home-based
parenteral nutrition (10 g to 3 L, 0.3% w ⁄ v) and
interrupted a constant sequence of severe catheter
infections with endocarditis in a male patient
aged 26 years with small-bowel disease [178].
A taurolidine lock (Taurolock; 5-mL ampoules
containing taurolidine 1.35% w ⁄ v and citrate
4% w ⁄v) can also be used for secondary prophy-
laxis [117] and to accompany antibiotic adminis-
tration during the treatment of CVAD-related
infections [118].
Urokinase
The results of in-vitro experiments, well-per-
formed prophylaxis studies [179,180], non-inter-
vention trials and clinical studies [63] all favour
the adjuvant use of urokinase in Gram-positive
catheter-related infections (for an overview, see
Kellerman et al. [181]), as urokinase probably
interferes with microthrombi and the integrity of
the bioﬁlm, which both impede the activity of
antibiotics against embedded bacteria. The clin-
ical workﬂow required for the judicious use of
urokinase is simpliﬁed by the introduction of a
department-speciﬁc ‘urokinase standard’. Uro-
kinase (i.e., Urokinase HS medac, 10 000 IU) is
diluted with sterile distilled water. The volume
instilled should not be greater than the CVAD
lumen. In the case of double-lumen systems, the
overall dose must be distributed between both
lumina. The general dosage regimen used at the
Department for Paediatric Haematology and
Oncology (University of Bonn, Germany) is: 3–
10 kg body weight, 2500 U; > 10–25 kg body
weight, 5000 U; and > 25 kg body weight,
10 000 U. After a dwell time of ‡ 4 h, the urokin-
ase lock is aspirated under sterile conditions and
used for an aerobic blood culture. The CVAD is
rinsed with NaCl 0.9% w ⁄v containing heparin
10 000 U ⁄L, and then attached immediately to the
antibiotic infusion. This procedure is repeated
after a further 24 h. Jones et al. [182,183] were able
to treat 59 (88%) of 67 CVAD-related Gram-
positive bacteraemias successfully in situ using
this approach.
CONCLUSIONS
Various new diagnostic procedures and thera-
peutic approaches have been developed recently.
Diagnostic methods such as DTP can identify a
catheter as the source of infection with high
sensitivity and speciﬁcity. However, such meth-
ods can be implemented only with difﬁculty into
the daily clinical routine. Furthermore, these tests
will only inﬂuence therapeutic decisions if cath-
eter explantation is considered. There is now
sufﬁcient evidence for in-situ treatment of CVAD-
associated infection in many cases, and additional
data continue to be gathered on the efﬁcacy of
ALT. Nevertheless, some questions still remain to
be answered. What is the optimal duration of
systemic antimicrobial treatment in uncompli-
cated CVAD infection? What is the optimal
concentration and duration of ALT? Are there
any validated criteria to decide which CVAD-
related infections caused by S. aureus or Gram-
negative bacteria can be treated safely in situ?
Does adjuvant treatment with urokinase or taur-
olidine improve signiﬁcantly the therapeutic suc-
cess rate? Evidence to address these questions
from randomised trials is awaited.
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